ESP Code of Transparency
The European Society of Pathology (ESP) is committed to transparency regarding its funding and financial governance.
The information below is based on the latest available Financial Report, which was approved by the ESP Council in February 2026 and audited by external auditors. Formal approval by the ESP General Assembly is expected in September 2026.
Funding Sources
Industry funding
In 2025, ESP received funding from the following industry partners:
- 3DHISTECH Ltd.
- Astellas
- AstraZeneca
- Amgen
- Daiichi-Sankyo
- Eli Lilly
- Exact Sciences
- GSK
- Incyte
- Johnson & Johnson
- Merck Sharp & Dohme (MSD)
- Pierre Fabre
- ROCHE
- Sakura Finetek
- ThermoFisher Scientific
In addition, ESP receives industry funding through sponsorship and exhibition activities associated with the European Congress of Pathology (ECP).
An overview of all sponsors and exhibitors of the 37th European Congress of Pathology (ECP 2025), held in Vienna, is available here.
Non-industry funding
ESP also receives funding from non-industry sources, including:
- Congress revenue
- Educational course revenue
- Virchows Archiv (editorial fees and royalties)
- Membership fees
- Grants
- Financial income
- Various reimbursements
Funding Composition
| Founding Source | Proportion of total income |
|---|---|
| Non-industry Funding | 42.83% |
| Industry Funding | 57.17% |
Highest contribution from a single company
The highest contribution from a single company represented 9.10% of ESP’s total income.